Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B

Figure 1 Time course after treatment with adefovir dipivoxil with or without lamivudine and entecavir for chronic hepatitis B patients. A: Changes in mean creatinine level; B: Mean estimated glomerular filtration rate (eGFR) with adefovir dipivoxil (ADV) and entecavir (ETV) administration.

Figure 2 Cumulative incidence of urine microprotein abnormalities after treatment with adefovir dipivoxil with or without lamivudine or entecavir in chronic hepatitis B patients. Cumulative incidence of A: Urine β2-microglobulin abnormality; and B: Retinol-binding protein abnormality with long-term adefovir dipivoxil (ADV) or entecavir (ETV) treatment.

Figure 3 Changes in urine microproteins after modification of adefovir dipivoxil treatment in chronic hepatitis B patients. A: Mean urine β2-microglobulin (β2-M); B: Mean urine retinol-binding protein (RBP) after switching to entecavir treatment [adefovir dipivoxil (ADV) to entecavir (ETV)] or with continued ADV treatment.